Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The adaptive immune response is a major determinant of the clinical outcome after SARS-
CoV-2 infection and underpins vaccine efficacy. T cell responses develop early and …

Abstract SARS-CoV-2, the virus responsible for the COVID-19 pandemic, has been
associated with substantial global morbidity and mortality. Despite a tropism that is largely …

Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …

Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …

Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …

Importance Continuous positive airway pressure (CPAP) and high-flow nasal oxygen
(HFNO) have been recommended for acute hypoxemic respiratory failure in patients with …

Although respiratory failure and hypoxaemia are the main manifestations of COVID-19,
kidney involvement is also common. Available evidence supports a number of potential …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

The emergence of SARS-CoV-2 triggering the COVID-19 pandemic ranks as arguably the
greatest medical emergency of the last century. COVID-19 has highlighted health disparities …